Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially on November 18th on IM8health.com CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics’ (NASDAQ:PRE) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic... Read More

Mission Launched via SpaceX CRS-31; Experiment Now Underway on the ISS Collaboration Aims to Enhance Healthspan on Earth and Improve Astronaut Health in Space IM8, a new premium supplements brand launched officially on November 18 th on IM8health.com CHARLOTTE, N.C., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Prenetics ’ IM8 is excited to announce that its groundbreaking month-long space experiment, in partnership with the University... Read More

CHARLOTTE, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited, (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced that members of the Prenetics management team will participate in two upcoming investor conferences. iAccess Alpha Virtual Best Ideas Winter Conference 2024 Date: December 10-11, 2024 Location: Virtual Presentation: December 10, 2024 at 10:00am ET... Read More

Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta’s Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today... Read More

Beckham is a strategic investor in Prenetics and Co-Founding Partner for IM8 IM8 launch marks a bold entry into the $187 billion global consumer health market Launch follows recently announced Prenetics’ acquisition of Europa, one of the largest sports nutrition distributors in the U.S. IM8 is now available at... Read More

Beckham is a strategic investor in Prenetics and Co-Founding Partner for IM8 IM8 launch marks a bold entry into the $187 billion global consumer health market Launch follows recently announced Prenetics’ acquisition of Europa, one of the largest sports nutrition distributors in the U.S. IM8 is now available at www.IM8health.com , shipping to 31 countries CHARLOTTE, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Prenetics , (NASDAQ:... Read More

CHARLOTTE, N.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Prenetics , (NASDAQ: PRE) a leading health sciences company, announced today that management will participate in the Sidoti Virtual Micro Cap Conference being held on November 13-14, 2024. Prenetics’ Chief Executive Officer Danny Yeung and Chief Financial Officer Stephen Lo will present virtually on Wednesday, November 13 th at 8:30 a.m. ET. A link to the webcast can be... Read More

HONG KONG, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, today announced that Tencent has made a strategic US$30 million investment in Insighta, a Hong Kong-based early cancer detection company. This investment values Insighta at US$200 million and underscores Tencent’s endeavor to advancing AI-powered innovations in healthcare. Following the transaction,... Read More

Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024 Enters U.S. Health Market in October with IM8, a New Health and Wellness Brand Re-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the second quarter... Read More

Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics’ New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences... Read More

Beckham becomes a strategic investor in Prenetics Beckham and Prenetics are co-founding partners for IM8, a new health and wellness brand LOS ANGELES, July 11, 2024 (GLOBE NEWSWIRE) -- Prenetics , (NASDAQ: PRE) a leading health sciences company, is proud to announce that former international footballer, entrepreneur and... Read More

LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company’s Board of Directors. “We are excited to welcome Kathryn and David to Prenetics’ Board of Directors at this pivotal juncture,” said Danny Yeung, CEO of Prenetics. “Their unparalleled... Read More

First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market Reaffirms 2024 Revenue Range of US$33 million to US$36 million LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results... Read More

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, has engaged international investor relations specialists MZ Group ("MZ") to lead a comprehensive strategic investor relations and financial communications program across all key markets. MZ Group will work closely with Prenetics management to develop and... Read More

HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates. Financial Highlights Revenue from continuing operations of US$21.7 million in the full year 2023, an increase of 65.2%... Read More

Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in space Dr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory Board Inaugural research cube scheduled to be... Read More

HONG KONG, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates. Third Quarter 2023 Financial Highlights Revenue from continuing operations of US$4.9 million Adjusted EBITDA from continuing operations of... Read More

HONG KONG, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading-genomics-driven health sciences company today announced that it will proceed with a reverse stock split of its outstanding ordinary shares at a ratio of 1-for-15. The reverse stock split is expected to become effective on or around November 13, 2023, subject to confirmation by NASDAQ. The Company’s common stock is expected to begin... Read More

HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates. Second Quarter 2023 Financial Highlights Revenue from continuing operations of US$5.7 million Adjusted EBITDA from continuing operations of... Read More

Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. Insighta is powered by technology developed by the Centre for Novostics which is supported by the InnoHK Initiative of the Innovation and Technology Commission of the Hong Kong SAR Government. By 2030, the early cancer detection screening opportunity is... Read More

HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the first quarter ended March 31, 2023, along with recent business updates. First Quarter 2023 Financial Highlights Revenue of US$17.7 million Adjusted EBITDA of US$(5.7) million Cash and other short-term assets 1 of... Read More

LONDON and HONG KONG, March 14, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results for the fourth quarter and full year ended December 31, 2022. Financial Highlights Revenue of US$275.8 million in the full year 2022 Revenue of US$52.3 million in the fourth quarter 2022 Adjusted EBITDA of US$58.3... Read More

LONDON and HONG KONG, March 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the ‘SAB’) to provide strategic input based on their scientific knowledge and clinical expertise to help guide the further development of Prenetics’ diagnostic cancer genomics platform. Prenetics has been... Read More

LONDON and HONG KONG, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14 to February 16, 2023. About Prenetics Founded in 2014, Prenetics is a major global diagnostic and genetic testing company... Read More

LONDON and HONG KONG, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure the company realizes the full potential of its broad genetics and digital testing platform and as a commitment to the EMEA market. To be effective immediately, Dr. Bayju Thakar is appointed as CEO and shall join the board of... Read More

Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market FDA market authorization advances personalized cancer care in Asia Clearance sets the stage for continued R&D investment into early detection / liquid biopsy LONDON and HONG KONG, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic... Read More

Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform Cancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail (acquired by Illumina), Exact Sciences, Guardant Health and more Expects ACT to contribute US$25-30 million in revenues in 2023... Read More